Q-omics provides the consensus-scored MTCO1P6 profile across patient tissues and cancer cell-line models. MTCO1P6 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, MTCO1P6 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, MTCO1P6 RNA expression shows 6,048 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, KICH, and STAD as cancer lineages where MTCO1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO1P6 survival associations across molecular data types. MTCO1P6 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO1P6 RNA expression–survival associations across cancer types. High MTCO1P6 expression shows unfavorable associations in CHOL, UVM, BRCA, THYM, DLBC and COAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for MTCO1P6 RNA expression.
This table summarizes MTCO1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO1P6 shows higher tumor expression in KICH, BRCA, COAD and THCA. The KICH box plot shows higher MTCO1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p = .010).
This table shows molecular features associated with MTCO1P6 in patient tissues and cancer cell lines. In patient samples, MTCO1P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
